BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Irwin N, Flatt PR. New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. World J Diabetes 2015; 6(15): 1285-1295 [PMID: 26557956 DOI: 10.4239/wjd.v6.i15.1285]
URL: https://www.wjgnet.com/1948-9358/full/v6/i15/1285.htm
Number Citing Articles
1
Di Zhang, Mingzhu Ma, Yueze Liu. Protective Effects of Incretin Against Age-Related DiseasesCurrent Drug Delivery 2019; 16(9): 793 doi: 10.2174/1567201816666191010145029
2
Suzanne M. de la Monte. Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer’s DiseaseDrugs 2017; 77(1): 47 doi: 10.1007/s40265-016-0674-0
3
S.L. Craig, R.A. Perry, S.S. Vyavahare, M.T. Ng, V.A Gault, P.R Flatt, N. Irwin. A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed miceBiochemical Pharmacology 2020; 171: 113723 doi: 10.1016/j.bcp.2019.113723
4
Angelica Artasensi, Alessandro Pedretti, Giulio Vistoli, Laura Fumagalli. Type 2 Diabetes Mellitus: A Review of Multi-Target DrugsMolecules 2020; 25(8): 1987 doi: 10.3390/molecules25081987
5
Shruti Mohan, R. Charlotte Moffett, Keith G. Thomas, Nigel Irwin, Peter R. Flatt. Vasopressin receptors in islets enhance glucose tolerance, pancreatic beta-cell secretory function, proliferation and survivalBiochimie 2019; 158: 191 doi: 10.1016/j.biochi.2019.01.008
6
Carmen Gloria Aylwin H.. NUEVOS FÁRMACOS EN DIABETES MELLITUSRevista Médica Clínica Las Condes 2016; 27(2): 235 doi: 10.1016/j.rmclc.2016.04.013
7
Srividya Vasu, Mary K McGahon, R Charlotte Moffett, Tim M Curtis, J Michael Conlon, Yasser H A Abdel-Wahab, Peter R Flatt. Esculentin-2CHa(1–30) and its analogues: stability and mechanisms of insulinotropic actionJournal of Endocrinology 2017; 232(3): 423 doi: 10.1530/JOE-16-0453
8
Patricio Atanes, Inmaculada Ruz-Maldonado, Shanta J. Persaud. Comprehensive Pharmacology2022; : 244 doi: 10.1016/B978-0-12-820472-6.00050-5
9
Altaf Al-Romaiyan, Shanta J. Persaud, Peter M. Jones. Identification of Potential Plant-Derived Pancreatic Beta-Cell-Directed Agents Using New Custom-Designed Screening Method: Gymnema sylvestre as an ExampleMolecules 2023; 29(1): 194 doi: 10.3390/molecules29010194
10
Galyna V. Graham, J. Michael Conlon, Yasser H. Abdel-Wahab, Peter R. Flatt. Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonistsMolecular and Cellular Endocrinology 2019; 480: 54 doi: 10.1016/j.mce.2018.10.011
11
Yanwei Li, Lin Li, Christian Hölscher. Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseasesReviews in the Neurosciences 2016; 27(7): 689 doi: 10.1515/revneuro-2016-0018
12
Ananyaa Sridhar, Dawood Khan, Peter R. Flatt, Charlotte R. Moffett, Nigel Irwin. GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed micePeptides 2023; 169: 171093 doi: 10.1016/j.peptides.2023.171093
13
Sarah L Craig, Nigel Irwin, Victor A Gault. Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic DisordersClinical Medicine Insights: Endocrinology and Diabetes 2021; 14: 117955142110438 doi: 10.1177/11795514211043868
14
Eko Fuji Ariyanto, Abdan Syakura Danil, Enny Rohmawaty, Budi Sujatmiko, Afiat Berbudi. Effect of Resveratrol in Melinjo Seed (Gnetum gnemon L.) Extract on Type 2 Diabetes Mellitus Patients and its Possible Mechanism: A ReviewCurrent Diabetes Reviews 2023; 19(2) doi: 10.2174/1573399818666220228160908
15
F. P. M. O'Harte, M. T. Ng, A. M. Lynch, J. M. Conlon, P. R. Flatt. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet‐induced obese diabetic miceDiabetes, Obesity and Metabolism 2016; 18(10): 1013 doi: 10.1111/dom.12713
16
Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin. Emerging therapeutic potential for peptide YY for obesity-diabetesPeptides 2018; 100: 269 doi: 10.1016/j.peptides.2017.11.005
17
Carlota Recio, Francesco Maione, Asif J. Iqbal, Nicola Mascolo, Vincenzo De Feo. The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular DiseaseFrontiers in Pharmacology 2017; 7 doi: 10.3389/fphar.2016.00526
18
Zhiguo Wang, Baofeng Yang. Polypharmacology2022; : 199 doi: 10.1007/978-3-031-04998-9_5
19
S.L. Craig, V.A. Gault, S. McClean, G. Hamscher, N. Irwin. Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolismMolecular and Cellular Endocrinology 2019; 496: 110523 doi: 10.1016/j.mce.2019.110523
20
Nigel Irwin, Victor A. Gault, Finbarr P.M. O’Harte, Peter R. Flatt. Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetesPeptides 2020; 125: 170203 doi: 10.1016/j.peptides.2019.170203
21
Yuka Kohda. Age-related hepatic glucose-dependent insulinotropic polypeptide expression is modified by ongoing thiamine supplementation in obese diabetic ratsFundamental Toxicological Sciences 2020; 7(6): 291 doi: 10.2131/fts.7.291
22
Pádraigín A. Harnedy-Rothwell, Chris M. McLaughlin, Aurélien V. Le Gouic, Ciaran Mullen, Vadivel Parthsarathy, Philip J. Allsopp, Emeir M. McSorley, Richard J. FitzGerald, Finbarr P. M. O’Harte. In Vitro and In Vivo Effects of Palmaria palmata Derived Peptides on Glucose MetabolismInternational Journal of Peptide Research and Therapeutics 2021; 27(3): 1667 doi: 10.1007/s10989-021-10199-8
23
Neil Tanday, Peter R. Flatt, Nigel Irwin. Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligandsBritish Journal of Pharmacology 2022; 179(4): 526 doi: 10.1111/bph.15485
24
Dawood Khan, Charlotte R. Moffet, Peter R. Flatt, Catriona Kelly. Role of islet peptides in beta cell regulation and type 2 diabetes therapyPeptides 2018; 100: 212 doi: 10.1016/j.peptides.2017.11.014
25
Walter Ramsey, Carlos M. Isales. Understanding the Gut-Bone Signaling AxisAdvances in Experimental Medicine and Biology 2017; 1033: 13 doi: 10.1007/978-3-319-66653-2_2
26
Namrata Prajapati, Dilip Sharma, Pankaj Ashok Bidve, Deepak Chouhan, Meghana Allani, Sagar kumar Patel, Moumita Ghosh Chowdhury, Amit Shard, Vinod Tiwari. Glucose regulation by newly synthesized boronic acid functionalized molecules as dipeptidyl peptidase IV inhibitor: a potential compound for therapeutic intervention in hyperglycaemiaJournal of Biomolecular Structure and Dynamics 2024; 42(6): 2859 doi: 10.1080/07391102.2023.2215319
27
Aimee Coulter-Parkhill, Stephen McClean, Victor A Gault, Nigel Irwin. Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for DiabetesClinical Medicine Insights: Endocrinology and Diabetes 2021; 14: 117955142110060 doi: 10.1177/11795514211006071
28
Brian M Moran, Aine M McKillop, Finbarr PM O’Harte. Development of novel ligands for peptide GPCRsCurrent Opinion in Pharmacology 2016; 31: 57 doi: 10.1016/j.coph.2016.08.009
29
S.L. Craig, V.A. Gault, C.E. Shiels, G. Hamscher, N. Irwin. Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite controlBiochimica et Biophysica Acta (BBA) - General Subjects 2021; 1865(8): 129917 doi: 10.1016/j.bbagen.2021.129917
30
IZ Qureshi, I Fatima. Peripherally administered KP-10 prevents development of insulin-induced hypoglycemic shock in diabetic rhesus monkeysPhysiology International 2020; 106(4): 335 doi: 10.1556/2060.106.2019.31
31
Anand-Krishna Singh, Rameshwar Jatwa, Ashok Purohit, Heera Ram. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetesJournal of Asian Natural Products Research 2017; 19(10): 1036 doi: 10.1080/10286020.2017.1307183
32
Finbarr P. M. O’Harte, Vadivel Parthsarathy, Christopher Hogg, Peter R. Flatt, Christian Holscher. Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed micePLOS ONE 2018; 13(8): e0202350 doi: 10.1371/journal.pone.0202350
33
Galyna V. Graham, Andrew McCloskey, Yasser H. Abdel-Wahab, J. Michael Conlon, Peter R. Flatt. A long-acting, dual-agonist analogue of lamprey GLP-1 shows potent insulinotropic, β-cell protective, and anorexic activities and improves glucose homeostasis in high fat-fed miceMolecular and Cellular Endocrinology 2020; 499: 110584 doi: 10.1016/j.mce.2019.110584
34
Clifford J. Rosen, Julie R. Ingelfinger. Shifting Tides Offer New Hope For ObesityNew England Journal of Medicine 2022; 387(3): 271 doi: 10.1056/NEJMe2206939
35
Dipak Sarnobat, R. Charlotte Moffett, Victor A. Gault, Neil Tanday, Frank Reimann, Fiona M. Gribble, Peter R. Flatt, Nigel Irwin. Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic GluCreERT2;ROSA26-eYFP micePeptides 2020; 125: 170205 doi: 10.1016/j.peptides.2019.170205
36
Seunghun P. Lee, Jenson Qi, Guozhang Xu, Matthew M. Rankin, James Littrell, June Zhi Xu, Ivona Bakaj, Alessandro Pocai. GRK Inhibition Potentiates Glucagon-Like Peptide-1 ActionFrontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.652628
37
N.M. Pathak, V. Pathak, V.A. Gault, S. McClean, N. Irwin, P.R. Flatt. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potentialBiochemical Pharmacology 2018; 155: 264 doi: 10.1016/j.bcp.2018.07.021
38
Rachele A. Perry, Sarah. L. Craig, Victor A. Gault, Peter R. Flatt, Nigel Irwin. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed miceBioscience Reports 2021; 41(8) doi: 10.1042/BSR20211275
39
Angelica Artasensi, Andrea Angeli, Carmen Lammi, Carlotta Bollati, Silvia Gervasoni, Giovanna Baron, Rosanna Matucci, Claudiu T. Supuran, Giulio Vistoli, Laura Fumagalli. Discovery of a Potent and Highly Selective Dipeptidyl Peptidase IV and Carbonic Anhydrase Inhibitor as “Antidiabesity” Agents Based on Repurposing and Morphing of WB-4101Journal of Medicinal Chemistry 2022; 65(20): 13946 doi: 10.1021/acs.jmedchem.2c01192
40
María Méndez, Hans Matter, Elisabeth Defossa, Michael Kurz, Sylvain Lebreton, Ziyu Li, Matthias Lohmann, Matthias Löhn, Hartmut Mors, Michael Podeschwa, Nils Rackelmann, Jens Riedel, Pavel Safar, David S. Thorpe, Matthias Schäfer, Dietmar Weitz, Kristin Breitschopf. Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R)Journal of Medicinal Chemistry 2020; 63(5): 2292 doi: 10.1021/acs.jmedchem.9b01071
41
Ryan A. Lafferty, Finbarr P. M. O’Harte, Nigel Irwin, Victor A. Gault, Peter R. Flatt. Proglucagon-Derived Peptides as TherapeuticsFrontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.689678
42
Flavia Prodam, Simonetta Bellone, Roberta Ricotti, Alice Monzani, Giulia Genoni, Enza Giglione, Gianni Bona. Neonatology2018; : 535 doi: 10.1007/978-3-319-29489-6_184
43
Srividya Vasu, Opeolu O. Ojo, R. Charlotte Moffett, J. Michael Conlon, Peter R. Flatt, Yasser H. A. Abdel-Wahab. Anti-diabetic actions of esculentin-2CHa(1–30) and its stable analogues in a diet-induced model of obesity-diabetesAmino Acids 2017; 49(10): 1705 doi: 10.1007/s00726-017-2469-3
44
Shruti Mohan, Peter R. Flatt, Nigel Irwin, R. Charlotte Moffett. Weight‐reducing, lipid‐lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in high‐fat‐fed miceDiabetes, Obesity and Metabolism 2021; 23(10): 2215 doi: 10.1111/dom.14462
45
Asif Ali, Peter R Flatt, Nigel Irwin. Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes MellitusClinical Medicine Insights: Endocrinology and Diabetes 2024; 17 doi: 10.1177/11795514241238059
46
T.D. Müller, B. Finan, S.R. Bloom, D. D'Alessio, D.J. Drucker, P.R. Flatt, A. Fritsche, F. Gribble, H.J. Grill, J.F. Habener, J.J. Holst, W. Langhans, J.J. Meier, M.A. Nauck, D. Perez-Tilve, A. Pocai, F. Reimann, D.A. Sandoval, T.W. Schwartz, R.J. Seeley, K. Stemmer, M. Tang-Christensen, S.C. Woods, R.D. DiMarchi, M.H. Tschöp. Glucagon-like peptide 1 (GLP-1)Molecular Metabolism 2019; 30: 72 doi: 10.1016/j.molmet.2019.09.010
47
F.P.M. O'Harte, M.T. Ng, A.M. Lynch, J.M. Conlon, P.R. Flatt. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in miceMolecular and Cellular Endocrinology 2016; 431: 133 doi: 10.1016/j.mce.2016.05.012
48
John B. Furness, Jeremy J. Cottrell. Signalling from the gut lumenAnimal Production Science 2017; 57(11): 2175 doi: 10.1071/AN17276
49
Yuka Kohda, Chiaki Minamigawa, Mikako Matsuo, Hitoshi Matsumura. Streptozotocin-induced diabetic state triggers glucose-dependent insulinotropic polypeptide (GIP) expression in the rat liverFundamental Toxicological Sciences 2016; 3(6): 291 doi: 10.2131/fts.3.291
50
Ryan A. Lafferty, Finbarr P.M. O’Harte, Nigel Irwin, Peter R. Flatt, Victor A. Gault. Comprehensive Pharmacology2022; : 301 doi: 10.1016/B978-0-12-820472-6.00035-9
51
Flavia Prodam, Simonetta Bellone, Roberta Ricotti, Alice Monzani, Giulia Genoni, Enza Giglione, Gianni Bona. Neonatology2016; : 1 doi: 10.1007/978-3-319-18159-2_184-1